Codeïnefosfaat

Product Beschrijving

Meta Description:

Comprehensive UK clinical and forensic monograph on Codeine Phosphate detailing semi-synthetic morphinan prodrug neuropharmacology, CYP2D6 bioactivation to morphine, pharmacogenetic metabolic stratification, neonatal and pediatric respiratory hazards, abuse liabilities (“lean”), and UK Class B / Schedule 2 & 5 controlled drug regulations.

1. Classification and Chemical Overview

Codeine phosphate is a licensed naturally occurring and semi-synthetic phenanthrene alkaloid belonging to the opioid analgesic and antitussive classes (originally isolated from the opium poppy, Papaver somniferum, and commercialized across the United Kingdom as multi-source generic formulations and proprietary brands such as Codis 500, combined preparations like Co-codamol, and historic single-agent syrups). Chemically designated as $(5R,6S,9R,13S,14R)\text{-3-methoxy-17-methyl-4,5-epoxymorphin-6-ol phosphate hemihydrate}$, codeine is the monomethyl ether derivative of morphine ($3\text{-O-methylmorphine}$). Structurally, it features a rigid pentacyclic morphinan core characterized by an ether (furan) bridge between carbon-4 and carbon-5, an aromatic A-ring bearing a methoxy substituent at carbon-3, a cyclohexenol C-ring with an allylic secondary hydroxyl at carbon-6, and a tertiary $N$-methylated bridge at position 17. The methoxy substitution at carbon-3 severely limits direct steric and electrostatic engagement with the orthosteric binding pocket of human opioid receptors, rendering parent codeine essentially an inactive metabolic prodrug. Its empirical molecular formula as the hemihydrate phosphate salt is $\text{C}_{18}\text{H}_{21}\text{NO}_3\cdot\text{H}_3\text{PO}_4\cdot\frac{1}{2}\text{H}_2\text{O}$, with an average molecular weight of $406.4\text{ g/mol}$ (unconjugated codeine base: $299.36\text{ g/mol}$).

Standard solid and liquid pharmaceutical presentations of single-agent Codeine Phosphate in the United Kingdom include:

• Immediate-Release Oral Tablets: White, round, biconvex or flat-faced compressed tablets in standardized single-agent strengths of $15\text{ mg}$, $30\text{ mg}$, En $60\text{ mg}$ of codeine phosphate hemihydrate (typically debossed with strength identifiers such as “CP 30” or manufacturer logos). Common excipients include lactose monohydrate, maize starch, pregelatinized starch, magnesium stearate, and colloidal anhydrous silica.

• Oral Solutions / Linctuses: Liquid presentations traditionally delivering $15\text{ mg}/5\text{ mL}$ ($3\text{ mg/mL}$) or pediatric/dilute variants delivering $3\text{ mg}/5\text{ mL}$.

• Parenteral Preparations: Solution for intramuscular or subcutaneous injection (typically $60\text{ mg}/1\text{ mL}$ ampoules; strictly avoiding intravenous administration due to acute histaminergic cardiovascular collapse).

Within the United Kingdom regulatory framework:

• Medicinal Classification: Single-agent solid dose tablets ($15\text{ mg}$, $30\text{ mg}$, $60\text{ mg}$), parenteral solutions, and oral linctuses are categorized as Prescription Only Medicines (POM) under the Human Medicines Regulations 2012.

  • Regulatory Shift: Following extensive MHRA drug safety reviews regarding rising diversion and addiction, all oral codeine-containing linctuses and syrups were permanently reclassified from Pharmacy (P) to Prescription Only Medicines (POM) in February 2024.

  • Over-the-Counter Exemptions: Low-strength, short-term compound formulations (e.g., Co-codamol $8\text{ mg}/500\text{ mg}$ paracetamol) remain available under strict Pharmacy (P) supervision, legally restricted to a maximum 3-day treatment duration for acute, moderate pain.

• Controlled Drug Scheduling: Under the Misuse of Drugs Act 1971, codeine is scheduled as a Class B controlled substance. Under the Misuse of Drugs Regulations 2001:

  • Single-entity tablets, raw active pharmaceutical ingredients (API), and parenteral forms are placed in Schedule 2 (CD POM), subject to full Controlled Drug prescription writing standards (total quantity in words and figures, 28-day validity) and Safe Custody compliance.

  • Specified dilute compound oral preparations containing low concentrations of codeine combined with non-controlled medicinal substances (such as standard low-dose syrups or combination analgesics containing $\le 2.5\%$ codeine base) sit within Schedule 5 (CD Inv POM / CD Inv P), exempting them from statutory register-logging and safe custody requirements.

• NHS Formulary Positioning: Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff for Step 2 pain management and specific specialist indications.

In clinical toxicology, community addiction landscapes, and forensic monitoring, codeine phosphate is heavily diverted. Oral tablets are crushed and extracted for recreational consumption or converted into illicit semi-synthetic derivatives. Diverted tablets and imported or home-compounded syrups (used in “lean” concoctions) sourced from online black markets frequently contain counterfeit formulations adulterated with illicit designer benzodiazepines (e.g., bromazolam) or high-potency synthetic nitazene opioids (such as metonitazene or protonitazene), presenting extreme hazards of unexpected fatal respiratory arrest.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of codeine phosphate is defined by its role as an in vivo metabolic prodrug, with its clinical analgesia, respiratory depression, and euphoria driven primarily by its bioactivation into morphine:

• The Prodrug Paradigm and Relative Receptor Affinity:

  • Unconverted parent codeine displays exceptionally low intrinsic affinity for human $\mu$-opioid receptors (MOP / OPRM1)—possessing an affinity roughly $200\text{-fold}$ to $300\text{-fold}$ lower than morphine ($K_i > 1,000\text{ nM}$). It exhibits negligible direct intrinsic agonist efficacy at physiological concentrations.

  • Clinical therapeutic efficacy is contingent upon hepatic Phase I $O$-demethylation catalyzed by the polymorphic cytochrome P450 isoenzyme CYP2D6, which bioactivates approximately $5\text{ to }10\%$ of an administered codeine dose into free morphine.

• Postsynaptic $\mu$-Opioid (MOP) Receptor Signal Transduction:

  • Converted morphine binds as a full agonist to human $\mu$-opioid receptors distributed across laminae I and II of the spinal dorsal horn, the periaqueductal gray (PAG), thalamus, rostral ventromedial medulla (RVM), and cortical sensory regions:

  • Binding couples to pertussis toxin-sensitive heterotrimeric inhibitory $G_{\alpha i/o}$ proteins.

  • The dissociated $G_{\alpha}$ subunit inhibits adenylyl cyclase, lowering intracellular cyclic adenosine monophosphate (cAMP).

  • Simultaneously, the $G_{\beta\gamma}$ dimer inhibits presynaptic voltage-gated N-type calcium ($Ca^{2+}$) channels, preventing the depolarization-induced exocytosis of excitatory nociceptive neurotransmitters (substance P, calcitonin gene-related peptide [CGRP], and L-glutamate).

  • Concurrently, it opens postsynaptic G-protein-coupled inwardly rectifying potassium (GIRK) channels, inducing cellular potassium ion efflux. The resulting membrane hyperpolarization raises the threshold required for action potential propagation along ascending spinothalamic tracts, effectively interrupting the transmission of pain signals to higher cortical processing centers.

• Central Medullary Antitussive Mechanism:

  • Codeine blunts the cough reflex through direct depressant action within the nucleus tractus solitarii of the medulla oblongata.

  • In addition to $\mu$-opioid activation via converted morphine, parent codeine interacts with central non-opioid $\sigma$-receptors ($\sigma_1$), raising the sensory vagal threshold to mechanical and chemical airway stimulation and blunting efferent motor impulses directed to the diaphragm and intercostal musculature.

• Enteric and Pontomedullary Depression:

  • Activation of $\mu$-receptors within the pontomedullary respiratory pacemakers (pre-Bötzinger complex) blunts the sensitivity of central chemoreceptors to arterial carbon dioxide tension ($\text{PaCO}_2$) and hypoxia, resulting in dose-dependent central respiratory depression.

  • In the gastrointestinal tract, stimulation of myenteric $\mu$-receptors inhibits propulsive peristalsis and secretomotor fluid transport while increasing internal anal and ileocecal sphincter tone, driving severe constipation.

• Relative Potency:

  • Codeine phosphate is classified as a weak Step 2 opioid on the World Health Organization (WHO) analgesic ladder.

  • In clinical practice, oral codeine phosphate is approximately one-tenth to one-sixth as potent as oral morphine (i.e., $30\text{ to }60\text{ mg}$ of oral codeine phosphate is equianalgesic to approximately $5\text{ mg}$ of oral morphine sulphate).

3. Approved UK Clinical Indications and Therapeutic Scope

Codeine phosphate holds licensed therapeutic indications within the British National Formulary (BNF) and National Institute for Health and Care Excellence (NICE) clinical guidelines:

• Mild-to-Moderate Acute Pain (Step 2 WHO Ladder):

  • Indicated for the short-term relief of acute, moderate pain that is not alleviated by non-opioid analgesics (paracetamol, ibuprofen) alone in adults and adolescents aged 12 years and older:

  • Standard Adult Dosing: $30\text{ to }60\text{ mg}$ orally every 4 hours as clinically indicated, up to a maximum licensed ceiling of $240\text{ mg/day}$.

  • Adolescents (12 to 18 Years): $30\text{ to }60\text{ mg}$ every 6 hours as needed, adjusted by body weight ($0.5\text{ to }1\text{ mg/kg}$), strictly capped at a maximum of $240\text{ mg/day}$. Treatment duration must not exceed 3 days without medical re-evaluation.

• Symptomatic Relief of Dry, Non-Productive Cough (Adults $\ge 18$ Years):

  • Short-term relief of distressing, non-productive dry cough refractory to simple demulcents:

  • Standard Dosing: $15\text{ to }30\text{ mg}$ orally three to four times daily (maximum $120\text{ mg/day}$).

  • NICE Guidance Positioning: Under NICE Clinical Knowledge Summaries (CKS: Cough), routine prescription of codeine for acute cough is discouraged due to weak clinical trial efficacy, high dependence risks, and substantial adverse effect burdens. Non-medicated demulcents (e.g., glycerol, honey) represent the first-line recommendation.

• Symptomatic Relief of Acute Diarrhea:

  • Utilized short-term in adults for uncomplicated acute diarrhea or chronic diarrhea associated with intestinal resections/stomas refractory to loperamide:

  • Dosing: $15\text{ to }30\text{ mg}$ orally three to four times daily.

• Strict Pediatric Restrictions (MHRA Directives):

  • Contraindicated in all children under 12 years of age for any indication.

  • Contraindicated in all children and adolescents under 18 years of age following tonsillectomy or adenoidectomy performed for obstructive sleep apnea syndrome.

  • Contraindicated in adolescents aged 12 to 18 years who possess any degree of compromised respiratory function (neuromuscular disorders, severe asthma, cardiac disease).

• NICE Guidance on Chronic Primary Pain (NG193):

  • NICE explicitly advises against the initiation of opioids (including codeine) for chronic primary pain (e.g., fibromyalgia, non-specific lower back pain) due to absent long-term functional efficacy, rapid physical dependence, and the hazard of opioid-induced hyperalgesia (OIH).

In non-medical, recreational settings:

• Codeine phosphate tablets are diverted for oral ingestion, crushed for nasal insufflation (ineffective and severely irritant), or compounded into “lean” concoctions with sedating antihistamines (e.g., promethazine) to induce euphoric relaxation, somatic warmth, and mental detachment.

• Abused at supratherapeutic doses ($150\text{ to }400+\text{ mg}$) by opioid-dependent individuals to alleviate acute withdrawal symptoms during periods of abstinence from stronger opioids (heroin, methadone, oxycodone).

4. Pharmacokinetic Profile and Metabolic Fate

The pharmacokinetic behavior of codeine phosphate is characterized by rapid oral absorption, extensive first-pass hepatic extraction, complex parallel biotransformation, and high clinical vulnerability to CYP2D6 pharmacogenetic polymorphism:

Hepatic Biotransformation Cascades

1. Glucuronidation (Major Elimination Pathway, $\sim 70\text{ to }80\%$): Direct Phase II conjugation catalyzed by UDP-glucuronosyltransferase UGT2B7 converts codeine to codeine-6-glucuronide (C6G). C6G possesses modest affinity for $\mu$-opioid receptors and contributes partially to systemic analgesia and sedation.

2. $O$-Demethylation via CYP2D6 (Bioactivation Pathway, $\sim 5\text{ to }10\%$): Cytochrome P450 2D6 cleaves the 3-methoxy ether group to generate active free morfine. Converted morphine is subsequently conjugated by UGT2B7 into active, potent morphine-6-glucuronide (M6G) and neurotoxic morphine-3-glucuronide (M3G).

3. $N$-Demethylation via CYP3A4 ($\sim 10\%$): CYP3A4 mediates $N$-demethylation to yield norcodeine, an inactive metabolite that undergoes subsequent glucuronidation.

                     Codeine Phosphate
                             │
     ┌───────────────────────┼──────────────────────┐
     │ (~75%)                │ (~10%)               │ (~10%)
  UGT2B7                  CYP3A4                 CYP2D6
     │                       │                      │
     ▼                       ▼                      ▼
Codeine-6-              Norcodeine               Morphine
Glucuronide (C6G)       (Inactive)                  │
(Mildly Active)                                 UGT2B7
                                                    │
                                            ┌───────┴───────┐
                                            │ (~60%)        │ (~10%)
                                            ▼               ▼
                                           M3G             M6G
                                       (Neurotoxic)    (High MOP Potency)

The CYP2D6 Pharmacogenetic Dynamic

Because the CYP2D6 gene is highly polymorphic within global populations, therapeutic efficacy and toxicity profiles vary drastically according to patient genotype:

• Poor Metabolisers (PMs; $7\text{ to }10\%$ of Caucasian cohorts): Individuals possessing two non-functional alleles (e.g., *3, *4, *5, *6). PMs lack enzymatic capacity to bioactivate codeine into morphine; they experience negligible analgesic relief, yet remain fully susceptible to codeine-induced nausea, constipation, and mast-cell histamine degranulation.

• Intermediate Metabolisers (IMs): Display reduced enzymatic activity; analgesia may be suboptimal, often prompting non-responsive patients to seek higher doses.

• Extensive (Normal) Metabolisers (EMs): Standard therapeutic response; predictable, controlled conversion to morphine.

• Ultra-Rapid Metabolisers (UMs; up to $10\%$ of Caucasians, up to $29\%$ of specific North African, Middle Eastern, and Mediterranean populations): Individuals possessing gene duplications or amplifications of functional CYP2D6 alleles (e.g., *1xN, *2xN). UMs clear codeine rapidly into massive, uncontrolled concentrations of free circulating morphine. In UMs, standard therapeutic doses ($30\text{ to }60\text{ mg}$) precipitate catastrophic, unexpected central respiratory depression, profound comatose stupor, and fatal apnea.

5. Physiological Effects and Adverse Event Spectrum

Therapeutic administration delivers moderate analgesia, dampens the cough reflex, and induces mild sedation. However, widespread $\mu$-opioid receptor engagement and direct mast cell degranulation produce an extensive adverse event spectrum:

• Histaminergic Reactions (Very Common, $\ge 1/10$):

  • Codeine acts as a direct, non-immunological secretagogue triggering cutaneous and systemic mast cell degranulation. Ingestion drives acute systemic histamine release, presenting as intense generalized pruritus (itching), cutaneous facial flushing, urticaria, conjunctival injection, and bronchospasm (dangerous in asthmatics).

• Gastrointestinal and Autonomic Disturbances (Very Common to Common, $\ge 1/100$ to $\ge 1/10$):

  • Severe Constipation: Enteric $\mu$-opioid receptor activation inhibits propulsive peristalsis, increases sphincter tone, and delays colonic transit. Tolerance to constipation does not develop; co-prescribing a stimulant or osmotic laxative is standard clinical protocol for regular therapy.

  • Nausea and vomiting: Driven by direct chemical stimulation of dopamine $D_2$ en $\mu$-opioid receptors in the chemoreceptor trigger zone (CTZ) in the area postrema.

  • Xerostomia (dry mouth), dyspepsia, and abdominal cramping.

  • Sphincter of Oddi Spasm: Marked constriction of biliary and pancreatic sphincters elevates intrabiliary pressure, precipitating acute biliary colic or exacerbating pancreatitis.

• Central Nervous System and Neuropsychiatric Toxicity (Common):

  • Drowsiness, daytime somnolence, lightheadedness, dizziness, and cognitive clouding.

  • Euphoria (reinforcing psychological dependence) or paradoxical dysphoria, restlessness, and anxiety.

  • Confusion and visual hallucinations (disproportionately observed in elderly patients).

• Severe, Emergent and Life-Threatening Hazards:

  • Catastrophic Central Respiratory Depression: The primary cause of fatal poisoning. Blunting of the brainstem pre-Bötzinger complex produces severe bradypnea ($<8\text{ breaths/min}$), progressive cyanosis, stupor advancing to deep unarousable coma, hypercapnic acidosis, and fatal hypoxic cardiac arrest.

  • Synergistic Depressant Collapse (“Lean” Toxicity): Co-ingestion of codeine alongside alcohol, benzodiazepines, or first-generation sedating antihistamines (e.g., promethazine, hydroxyzine) synergistically suppresses brainstem respiratory pacing, exponentially increasing fatal poisoning rates.

  • Physical Dependence and Acute Opioid Withdrawal Syndrome: Continuous exposure exceeding 1 to 2 weeks drives neuroadaptation. Abrupt cessation triggers a classical opioid withdrawal syndrome:

    • Intense autonomic hyperactivity: sinus tachycardia, hypertension, profuse diaphoresis, rhinorrhea, and lacrimation.

    • Gastrointestinal distress: severe abdominal cramps, nausea, vomiting, and explosive diarrhea.

    • Piloerection (“cold turkey”), pupil dilation (mydriasis), severe myalgias, muscle twitches, and unremitting insomnia.

  • Fatal Intravenous Injection Hazard: Intravenous injection of codeine phosphate tablets or solutions carries extreme risks of catastrophic, non-immunological massive histamine degranulation, producing immediate severe hypotension, pulmonary edema, bronchospasm, cardiovascular collapse, and death. Parenteral administration is strictly restricted to intramuscular or subcutaneous routes.

  • Counterfeit Nitazene Adulteration: Illicitly sourced tablets sold as codeine phosphate frequently contain synthetic nitazene opioids (e.g., protonitazene, metonitazene), which exhibit potencies tens to hundreds of times higher than morphine, precipitating sudden, refractory respiratory collapse that requires massive, escalated doses of naloxone.

6. Contraindications, Drug Interactions, and Clinical Precautions

Safe prescribing, dispensing, and emergency evaluation of codeine phosphate require strict adherence to opioid safety guidelines, pharmacogenetic risk stratification, and respiratory contraindications:

• Contraindications:

  • Known CYP2D6 Ultra-Rapid Metabolisers: Absolute contraindication due to high risk of fatal morphine toxicity at standard doses.

  • Children Under 12 Years of Age: Absolute contraindication for all clinical indications.

  • Children and Adolescents Under 18 Years Post-Adenotonsillectomy: Absolute contraindication following tonsillectomy/adenoidectomy for obstructive sleep apnea.

  • Adolescents Aged 12 to 18 with Respiratory Impairment: Contraindicated in those with compromised respiratory function.

  • Acute Respiratory Compromise: Absolute contraindication in acute respiratory failure, severe chronic obstructive pulmonary disease (COPD), acute severe asthma, or compromised ventilatory drive.

  • Paralytic Ileus or Obstructive Bowel Disease: Absolute contraindication due to the risk of precipitating toxic megacolon or bowel perforation.

  • Raised Intracranial Pressure (ICP) and Severe Head Injury: Opioid-induced hypoventilation causes $\text{CO}_2$ retention, driving cerebral vasodilation that dangerously spikes intracranial pressure.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication during or within 14 days of MAOI therapy (risks hyperpyrexic crises and central collapse).

  • Pregnancy and Breastfeeding: Absolute contraindication during breastfeeding (morphine distributes into maternal milk, presenting severe risks of fatal neonatal apnea); chronic use during pregnancy risks neonatal opioid withdrawal syndrome (NOWS).

• Drug Interactions:

  • Central Nervous System Depressants (e.g., Alcohol, Benzodiazepines, Antipsychotics, Sedating Antihistamines): Major Synergistic Hazard. Profound, potentially fatal depression of the medullary ventilatory drive. Co-ingestion is the foundational mechanism of fatal recreational syrup poisonings.

  • CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine, Bupropion, Quinidine): Blocks the metabolic bioactivation of codeine to active morphine, completely abolishing analgesic and antitussive efficacy while leaving adverse histaminergic and gastrointestinal side effects unopposed.

  • CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St John’s Wort): Accelerates clearance to inactive norcodeine, significantly reducing clinical efficacy.

  • Anticholinergic Agents (e.g., TCAs, Antihistamines, Antimuscarinics): Compounded paralytic burden on the gastrointestinal tract and bladder, substantially increasing the risk of paralytic ileus and acute urinary retention.

• Clinical Precautions and Emergency Overdose Management (“Red Flags”):

  • Acute Overdose Resuscitation Protocol: Patients presenting to NHS emergency departments (999/A&E) with the classic opioid toxidrome (respiratory depression $<8\text{ breaths/min}$, pinpoint pupils [miosis], and coma/unresponsiveness) require immediate emergency stabilization:

    • Airway and Oxygenation: Prioritize airway patency, position in the recovery position, deliver high-flow oxygen, and support ventilation with bag-valve-mask or endotracheal intubation if respiratory failure supervenes.

    • Targeted Naloxone Administration: Administer the opioid antagonist naloxone ($400\text{ mcg}$ IV initially, repeating or escalating to $800\text{ mcg}$ to $2\text{ mg}$ every 2 to 3 minutes up to $10\text{ mg}$ as clinically indicated to restore adequate spontaneous respiration).

    • Prolonged Observation Window: Because converted morphine and active glucuronides have elimination half-lives ($2\text{ to }3.5\text{ hours}$) that outlast intravenous naloxone ($30\text{ to }60\text{ minutes}$ duration of action), patients must be observed under continuous pulse oximetry and clinical monitoring for a minimum of 4 to 6 hours to detect and manage re-narcotization.

    • Nitazene Suspicion: In patients who ingested counterfeit tablets containing synthetic nitazene opioids, massive cumulative doses of naloxone ($>4\text{ to }10\text{ mg}$ IV or continuous IV infusion) may be required to maintain ventilation.

  • Laxative Co-Prescribing: Prescribing standards mandate that any patient initiated on regular codeine phosphate therapy must be concurrently co-prescribed a prophylactic laxative regimen (combining an osmotic agent like macrogol with a stimulant laxative like senna) to prevent severe fecal impaction.

  • Detoxification Protocols: Dependent individuals attempting to discontinue codeine must not be stopped abruptly without clinical support. Management involves structured stabilization and gradual dose reduction using licensed oral opioid substitution therapy (e.g., buprenorphine or methadone) under NHS community addiction recovery services.

  • Driving Safety Warning: Codeine impairs cognitive processing and reaction times. Under Section 5A of the Road Traffic Act 1988, driving with specified controlled drugs in the blood above statutory limits is an offence; while a statutory medical defense applies when the medicine is taken strictly in accordance with prescription instructions, patients must be warned that driving while impaired remains an offence under Section 4 of the Act.

Aanvullende Informatie